A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Aim: To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity. Materials and methods: We investigated multiple rising doses of BI 456906 escalated over 16 weeks (maximum doses: 1.8 mg once weekly [dose group {DG} 1], 4.8 mg once weekly [DG 2] and 2.4 mg twice weekly [DG 3]) in Japanese men with a body mass index of 23 to 40 kg/m 2 . Results: Thirty‐six participants were treated (n = 9 per DG and placebo). Overall, 10 participants (37.0%) treated with BI 456906 withdrew from dose escalation due to adverse events (amylase increase, n = 1; decreased appetite, n = 9), and the proportion of participants was higher in DG 2 (n = 6, 66.7%) versus DGs 1 and 3 (both n = 2, 22.2%). No participants receiving placebo withdrew from dose escalation. BI 456906 exposure increased with dose and dose escalation in each DG. Treatment with BI 456906 decreased placebo‐corrected bodyweight after 16 weeks (placebo +1.06%): DG 1, −5.57%; DG 2, −12.37%; DG 3, −9.62%. Paracetamol absorption decreased in Week 1 for DGs 2 and 3, indicating transient delayed gastric emptying. BI 456906 reduced plasma alanine and glucagon levels, indicating indirect target engagement at GCGRs and GLP‐1Rs. Drug‐related adverse events were reported for all participants receiving BI 456906 and four receiving placebo, the most frequent being decreased appetite (n = 24, 66.7%). Conclusions: BI 456906 showed no unexpected tolerability concerns and it reduced placebo‐corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“9%), which, again, is typical of GLP-1R agonists, for which decreased appetite is a key mechanism contributing to reduced bodyweight.(17,38) Overall, the tolerability profile of BI 456906 in Japanese participants in the present study was similar to that observed in the European MRD study; European participants also re…”
ResultA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 3×
“People of Asian heritage have higher average body fat than those of European descent matched for age, sex and BMI,2 and a BMI of ≥23 kg/m2 is linked with an increased risk of concurrent diseases in Asian individuals.3 Therefore, the Japan Society for the Study of Obesity defines overweight as a BMI ≥23 kg/m2 and obesi…”
BackgroundMethodInfluentialLong-term weight-loss maintenance: a meta-analysis of US studies
Anderson, J. W., Konz, E. C., Frederich, R. C., & Wood, C. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.5.579 · Cited by 1,351 · cited 1×
“The current standard of care for people with obesity consists of lifestyle modifications, although any weight loss achieved in this way is difficult to maintain, and approximately 80% regain their lost weight after 5 years.(5) When lifestyle modifications alone fail to promote sustained weight reductions, guidelines r…”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“9%), which, again, is typical of GLP-1R agonists, for which decreased appetite is a key mechanism contributing to reduced bodyweight.(17,38) Overall, the tolerability profile of BI 456906 in Japanese participants in the present study was similar to that observed in the European MRD study; European participants also re…”
ResultA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228 · cited 1×
“0% after 26 weeks of treatment in the PIONEER 10 and 9 trials, respectively.(42,43) The dual GLP-1R/glucose-dependent insulinotropic polypeptide receptor agonist, tirzepatide has also been investigated in a Phase I trial of Japanese individuals with type 2 diabetes (mean baseline BMI 25.”
BackgroundYabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154 · cited 1×
“Individuals treated with GLP-1R agonists frequently report gastrointestinal disorders, such as nausea,(17,38) linked to delayed gastric emptying and central effects of GLP-1R agonism.(39,40) Drug-related decreased appetite was observed in the majority of BI 456906-treated individuals (88.”
BackgroundZimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149 · cited 4×
“BI 456906 is an acetylated peptide that contains a C18 fatty-acid as a half-life-extending principle, and it is an appropriately balanced dual agonist of GCGR and GLP-1R, with a relative receptor ratio of 1:8 observed in in vitro studies in human plasma.(36) BI 456906 is currently in development as a once-weekly, subc…”
BackgroundInfluentialUrva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77 · cited 1×
“Recent pharmacotherapies for obesity, such as glucagonlike peptide receptor (GLP-1R) agonists, target multiple pathways, including those involved in appetite, energy expenditure and glucose metabolism.(10) The GLP-1R agonists act via receptors in the brain and gut to reduce appetite, delay gastric emptying and improve…”
BackgroundJungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Self-citationIkushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Research works printed but not linked: 22
- World Health Organization, 2021, Fact Sheet on Obesity and Overweight
- 10.1016/S0140-6736(03)15268-3 · DOI · Paper page
- 10.1159/000088200 · DOI · Paper page
- 10.1016/j.jacc.2013.11.004 · DOI · Paper page
- Australian Department of Health National Health and Medical Research Council, 2013, Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults, Adolescents and Children in Australia
- 10.1159/000442721 · DOI · Paper page
- 10.1038/s41574-018-0118-x · DOI
- 10.1111/jdi.12464 · DOI · Paper page
- 10.21037/atm.2019.01.09 · DOI
- 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
- 10.1111/dom.12932 · DOI · Paper page
- U.S. Food & Drug Administration, FDA Approves New Drug Treatment for Chronic Weight Management, First since 2014
- U.S. Food & Drug Administration, 2020, FDA Approves Weight Management Drug for Patients Aged 12 and Older
- 10.2337/db09-0278 · DOI · Paper page
- 10.2337/db12-0797 · DOI · Paper page
- 10.1152/ajpendo.00576.2007 · DOI · Paper page
- 10.1210/en.2003-1338 · DOI · Paper page
- 10.1111/dom.14496 · DOI · Paper page
- 10.1111/dom.14572 · DOI · Paper page
- 10.1136/bmjdrc-2021-002208 · DOI
- 10.1111/j.1463-1326.2012.01557.x · DOI · Paper page
- Rosenstock J, 2022, SO46 613 multiple dose‐ranging study of the novel glucagon/GLP‐1 receptor dual agonist BI 456906 vs placebo and open‐label weekly semaglutide reference control in type 2 diabetes, Diabetologia, 65, S314
Cited by
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Review on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
Wan, H., Xu, N., Wang, L., Liu, Y., Fatahi, S., Sohouli, M. H., & Guimarães, N. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01501-x · Cited by 8
Metadata
- Authors
- Yazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-04-27
- Volume
- 25
- Issue
- 7
- Pages
- 1973-1984
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4361190240
- Cited by
- 23
- References
- 25
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Boehringer Ingelheim
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.